Back to results
US 6,660,259 B2Granted
Herpes simplex virus for treating unwanted hyperproliferative cell growth
AssigneeOnyx Pharmaceuticals, Inc.
InventorsSylvie Laquerre, Terry Hermiston
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions, kits, and methods of use thereof, comprising, a mutant human herpes simplex-type 1 virus, which is cytopathic to susceptible hyperproliferative cells, such as neoplastic cells. Preferably, the virus does not produce a fully functionally active wild-type ICP0 polypeptide coded for the IE gene 1.
Claims15
A method for treating a tumor in a cell population with a herpes simplex virus comprising neoplastic cells defective in beta-catenin metabolism, comprising:
- injecting said tumor with an amount of a mutant herpes simplex virus which is lytic to said cells, wherein said virus does not produce a functionally active wild-type ICP0 polypeptide coded for by the herpes simplex virus IE 1 gene 1, thereby allowing said virus to lysis said neoplastic cells.
Dependencies are inferred from the claim text.